Coronavirus Update: Clover Begins Twin Track Trials With GSK And Dynavax

Plus: Are UK's New Takeover Laws Prompted By AstraZeneca Fears?

Clover enters the clinical trial stage in race to develop a vaccine, while the UK moves to protect a range of key industries from foreign takeover, including vaccines manufacturers. Meanwhile, confirmed cases in Beijing continue to rise.    

Sharma_Alok
UK business minister Alok Sharma: new laws would allow government to block a vaccines company takeover.

China’s Clover Biopharmaceuticals has dosed the first volunteers in its COVID-19 vaccine candidate Phase I trials, and is testing it in conjunction with two separate adjuvants, one from GlaxoSmithKline PLC and the other from Dynavax Technologies Corp.

The start of Clover’s first-in-human studies on 19 June brings the total of major vaccine candidates in clinical trials to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D